SLC5A2 and diabetic kidney disease: In a tubule-centric view (29), the upregulation of SGLT1 and SGLT2 in PCT induced the alteration of glomerulotubular communication and hyperfiltration, explaining the renoprotective mechanisms of the novel agent SGLT2 inhibitor in DKD treatment (30–32).